Uni-Bio Science's strategic priorities :
Focus on endocrinology and related complications in areas such as ophthalmology and dermatology :
•
To develop a mature KOL and patient network in endocrinology and strengthen the Uni-Bio brand as a chronic disease management expert among these stakeholders
•
To increase the breadth of our sales coverage beyond the key provinces and realise the growth opportunities under the healthcare reform of the PRC market
•
To grow our diversified portfolio of innovative treatments and healthcare solutions through partnerships that address high unmet medical need to patients in China
•
To lower cost and simultaneously enhance product quality, so to bring much more value to patient
Our strategy is driven by our team of highly experienced professionals. A distinct combination of local knowledge and international experience equips us well to grow as a leading domestic healthcare company with a global outlook. This is an important foundation to bring world-class innovative therapeutics and products to the China market.
Furthermore, with a long-term commitment to serve in the chronic diseases domain, the Uni-Bio brand will continue to grow with a focused objective, ultimately securing sustainable growth opportunities as we become a respectable chronic disease management leader.
Uni-Bio Science's strength as an experienced Chinese healthcare company will enable the Group to leverage the growth drivers available to it in China, one of the world's largest healthcare markets.
•
Increasing healthcare spending
•
Healthcare reforms which will recognise and reward genuine innovation
•
Innovative products demonstrating resistance to downward pricing pressures
The launch of innovative proprietary medicines, combined with the successful execution of our partnering strategy, will spur growth in our business, reduce risk and create long-term value for shareholders.
京公网安备 11011402013046号京ICP备17029593号-2
